Загрузка...
First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China
BACKGROUND: IMpower 133 trial first confirmed the efficacy and safety of adding atezolizumab or placebo to first-line treatment with chemotherapy in patients with extensive-stage small-cell lung cancer (SCLC). While, overprice limited its broad use in clinical. The aim of this study was to evaluate...
Сохранить в:
| Опубликовано в: : | Chin Med J (Engl) |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Wolters Kluwer Health
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6940079/ https://ncbi.nlm.nih.gov/pubmed/31856049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CM9.0000000000000536 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|